Summary - Osteocyte control of bone formation via Sost/sclerostin

Journal of Musculoskeletal Neuronal Interactions

Volumn 6, Issue 4, 2006, Pages 360-363

  Bellido, Teresita ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; GLYCOPROTEIN; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE METABOLISM; DRUG MECHANISM; ENHANCER REGION; FAMILY STUDY; GENE EXPRESSION REGULATION; GENE LOCATION; GENE MAPPING; GENE MUTATION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOSCLEROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; WEIGHT BEARING;

EID: 33846260512     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem 1994; 55:287-299.
2. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102:274-282.
3. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85:2907-2912.
4. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. Non-genotropic, sex-non-specific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104:719-730.
5. Noble BS, Stevens H, Loveridge N, Reeve J. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone 1997; 20:273-282.
6. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 1997; 82:3128-3135.
7. Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998; 13:1243-1250.
8. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104:1363-1374.
9. Verborgt O, Gibson G, Schaffler MB. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 2000; 15:60-67.
10. Aguirre JI, Plotkin LI, Berryhill SB, Shelton RS, Stewart SA, Weinstein RS, Parfitt AM, Manolagas SC, Bellido T. Increased prevalence of osteocyte apoptosis precedes osteoclastic bone resorption and the loss of bone mineral and strength induced by lack of mechanical forces in a murine model of unloading. J Bone Miner Res 2004; 19:S137.
11. Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, Reeve J, Skerry TM, Lanyon LE. Mechanical loading: biphasic osteocyte survival and the targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol 2003; 284:C934-C943.
12. Hamaya M, Mizoguchi I, Sakakura Y, Yajima T, Abiko Y. Cell death of osteocytes occurs in rat alveolar bone during experimental tooth movement. Calcif Tissue Int 2002; 70:117-126.
13. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22:6267-6276.
14. Van Bezooijen RL, Roelen BA, Visser A, Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004; 199:805-814.
15. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblasto-genesis. Endocrinology 2005; 146:4577-4583.
16. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a WNT signaling inhibitor. J Biol Chem 2005; 280:26770-26775.
17. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280:19883-19887.
18. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003; 24:218-235.
19. Kolpakova E, Olsen BR. Wnt/beta-catenin - a canonical tale of cell-fate choice in the vertebrate skeleton. Dev Cell 2005; 8:626-627.
20. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10:537-543.
21. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68:577-589.
22. Warmington K, Morony S, Sarosi I, Gong G, Stepphens P, Winkler DG, Sutherland MK, Latham JA, Kirby H, Moore A, Robinson M, Kostenuik PJ, Simonet S, Lacey DL, Paszty C. Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood. J Bone Miner Res 2004; 19:S56.
23. Warmington K, Ominsky M, Bolon B, Cattley R, Stephens P, Lawson A, Lightwood D, Perkins V, Kirby H, Moore A, Robinson M, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss. J Bone Miner Res 2005; 20:S22.
24. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005; 15:928-935.
25. Van Hul W, Balemans W, Van HE, Dikkers FG, Obee H, Stokroos RJ, Hildering P, Vanhoenacker F, Van CG, Willems PJ. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17ql2-q21. Am J Hum Genet 1998; 62:391-399.
26. Balemans W, Van Den EJ, Freire Paes-Alves A, Dikkers FG, Willems PJ, Vanhoenacker F, de Almeida-Melo N, Alves CF, Stratakis CA, Hill SC, Van Hul W. Localization of the gene for sclerosteosis to the Van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet 1999; 64:1661-1669.
27. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Identification of a 52 kb deletion down-stream of the SOST gene in patients with van Buchem disease. J Med Genet 2002; 39:91-97.
28. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17ql2-q2l is associated with Van Buchem disease in the Dutch population. Am J Med Genet 2002; 110:144-152.
29. Schipani E, Kruse Y, Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995; 268:98-100.
30. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E. Activated parathyroid hormone/ parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 2001; 107:277-286.
31. Kalajzic: I, Braut A, Guo D, Jiang X, Kronenberg MS, Mina M, Harris MA, Harris SE, Rowe DW. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone 2004; 35:74-82.